Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Figs Inc (FIGS) vs Novo Nordisk A/S (NVO) Price & Performance

Novo Nordisk A/STrade

Price performance (Past 24H)

Key statistics

Figs Inc vs Novo Nordisk A/S — how do they compare? Figs Inc trades at $14.35 (market cap $2.37B), while Novo Nordisk A/S trades at $46.25 (market cap $207.85B). The key difference: Novo Nordisk A/S is far larger — about 87.7× Figs Inc's market cap, and Novo Nordisk A/S pays a 3.81% dividend while Figs Inc pays none. Which is the better fit depends on your goals.

FIGSNVO
Market Cap
$2.37B$207.85B
Sector
Consumer CyclicalHealth
52-Week High
$17.12$63.98
52-Week Low
$6.57$35.29
Enterprise Value
$2.13B$222.55B
Dividend Yield
3.81%

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Figs Inc

FIGS trades at $14.41, up 0.14% with strong technical momentum as moving averages signal bullish sentiment. The company reported impressive Q2 2026 results with 29% revenue growth and raised full-year guidance, while maintaining robust gross margins of 68.9%. Recent institutional buying and positive analyst coverage support the stock's upward trajectory despite rich valuation multiples.

Outlook remains positive with accelerating revenue growth and margin expansion, though the premium valuation (P/E 43.2) creates high expectations. Key risks include execution challenges in the second half and competitive pressures in healthcare apparel. The consensus price target of $19.50 suggests 35% upside potential from current levels.

Novo Nordisk A/S

Novo Nordisk (NVO) trades at $46.28, down 3.05% today, with technical indicators showing neutral signals. The company maintains strong fundamentals with Q2 2026 EPS beating expectations at $0.96 versus $0.77 estimate, continuing a pattern of earnings outperformance. Revenue growth remains solid with 2025 revenue reaching $309.1B and net income margin of 33.14%. Analyst sentiment remains positive with 57.9% recommending Buy, though recent news highlights competitive pressures from Eli Lilly in the GLP-1 market.

NVO presents a compelling investment case with robust profitability metrics including 59.82% ROE and attractive valuation at 11.62 P/E. However, increasing competition in weight-loss drugs and pricing pressures create headwinds. The stock's current technical neutrality suggests potential consolidation near current levels, with fundamental strength supporting long-term growth prospects despite near-term competitive challenges.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About Figs Inc

FIGS Inc is a healthcare apparel company. It offers more fitted scrubs for men and women made of its proprietary fabric FIONx, which provides four-way stretch and has anti-odor, anti-wrinkle, and moisture-wicking properties.

Read more on FIGS

About Novo Nordisk A/S

With almost 50% market share by volume of the global insulin market, Novo Nordisk is the leading provider of diabetes-care products in the world. Based in Denmark, the company manufactures and markets a variety of human and modern insulins, injectable diabetes treatments, and oral antidiabetic agents. Novo also has a biopharmaceutical segment (constituting roughly 15% of revenue) that specializes in protein therapies for hemophilia and other disorders.

Read more on NVO